ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

Employees - 16, CEO - Dr. Uttam Yashwant Patil Ph.D., Sector - Healthcare, Country - US, Market Cap - 11.87M

Altman ZScore(max is 10): -7.5, Piotroski Score(max is 10): 3, Working Capital: $-4167315, Total Assets: $14462845, Retained Earnings: $-70552277, EBIT: -6385421, Total Liabilities: $6483523, Revenue: $509788

AryaFin Target Price - $-0.59 - Current Price $0.91 - Analyst Target Price $20.20